赛升药业：2025年半年度净利润约4779万元

Core Viewpoint - The company reported a decline in revenue and a return to profitability in the first half of 2025 compared to the same period in 2024 [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 197 million yuan, representing a year-on-year decrease of 8.4% [2] - The net profit attributable to shareholders for the first half of 2025 was approximately 47.79 million yuan, with a basic earnings per share of 0.1 yuan [2] - In comparison, the revenue for the same period in 2024 was approximately 215 million yuan, with a net loss attributable to shareholders of about 105 million yuan and a basic loss per share of 0.22 yuan [2]